Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

3 Months Ended

Mar. 31, 2023

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

12. Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders

The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the three months ended March 31, 2023 and 2022 (in thousands, except share and per share amounts):


	Three Months Ended March 31,
	2023			2022
Net loss attributable to Adaptive Biotechnologies Corporation	$	(57,699	)	$	(62,736	)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted		143,511,142			141,697,252
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$	(0.40	)	$	(0.44	)

Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive.

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three months ended March 31, 2023 and 2022, as they had an anti-dilutive effect:


	Three Months Ended March 31,
	2023		2022
Stock options outstanding		13,800,485		13,255,459
Nonvested restricted stock units outstanding		7,386,862		2,587,492
Maximum nonvested market-based restricted stock units outstanding eligible to be earned		904,006		153,762
Total		22,091,353		15,996,713